A novel treatment for heart failure in cancer

Lead researcher

Dr Kate Murphy

Dr Kate Murphy

Institution

The University of Melbourne

Tumour type:

Bowel

Years funded

2017-2019

Project description

We will test the terapeutic potential of novel antibodies for reducing the heart failure associated with many cancers and chemotherapeutics. Our results will lead to better treatment approaches and improved health outcomes for cancer patients.

What are you trying to achieve?

There is an urgent need to treat the heart failure associated with many cancers, and to prevent the toxic effects that chemotherapies can have on the heart. We discovered that a certain type of signalling contributes to skeletal muscle wasting and weakness in cancer. This proposal will investigate whether this signalling pathway is similarly implicated in the development of heart failure in cancer and with chemotherapy, and whether blocking this pathway can improve health outcomes. 

What is your personal motivation?

Seeing family and friends suffering and ultimately losing their life to cancer is the motivation for my research.

Project timeline

2017  2018 
2019 

Investigate the mechanisms involved in induced cardiac cachexia

Investigate the efficacy of antibody-directed inhibition for treating cardiac cachexia in mice injected with colon cancer cells 

 

Investigate the efficacy of antibody-directed inhibition for treating cardiac cachexia in mice injected with colon cancer cells 

Investigate the therapeutic potential of antibody-directed inhibition for treating cardiac cachexia in a mouse model of pancreatic cancer 

   Investigate whether antibody-directed inhibition can attenuate cardiotoxicity and dysfunction and improve the response to chemotherapy in severely cachectic mice

 

 

"Our results will lead to better treatment approaches and improved health outcomes for cancer patients."

Collaborators

Prof John Silke, Prof Gordon Lynch, Prof Leanne Delbridge